JO3242B1 - طرق علاج داء السكري بمستضادات dll4 - Google Patents

طرق علاج داء السكري بمستضادات dll4

Info

Publication number
JO3242B1
JO3242B1 JOP/2017/0065A JOP20170065A JO3242B1 JO 3242 B1 JO3242 B1 JO 3242B1 JO P20170065 A JOP20170065 A JO P20170065A JO 3242 B1 JO3242 B1 JO 3242B1
Authority
JO
Jordan
Prior art keywords
dii4
methods
disorders
diseases
disease
Prior art date
Application number
JOP/2017/0065A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3242B1 publication Critical patent/JO3242B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يزود الاختراع الحالي طرقاً لمعالجة مرض أو اضطراب حيث ازدياد عدد الخلايا التائية التنظيمية مفيداً بإعطاء شخص أو حيوان يعاني من هذا المرض أو الاضطراب كمية فعالة علاجياً من مستضادات DII4 تعمل على سد مسارات إشارة DII4-NOTCH مما يزيد عدد الخلايا التائية. الأمراض أو الاضطرابات القابلة للمعالجة بطرق الاختراع تضم أمراض أو اضطرابات ذاتية المناعة مثل التصلب المتعدد والسكري وما شابه. مستضادات DII4 مناسبة للاختراع تشمل مضادات حيوية أو أجزاء مضاد حيوي تربط بصورة خاصة DII4 وتوقف تفاعلات DII4-NOTCH ونطاق DII4 خارج الخلية وما شابه. كما يزود الاختراع طرق منع وقوع أو تكرار وقوع هذه الأمراض أو الاضطرابات في شخص أو حيوان تعرض سابقاً أو عرضةً للإصابة بهذه الأمراض أو الاضطرابات. علاوةً على ذلك، طرق الاختراع مفيدة في منع أو معالجة رفض زراعة الأعضاء أو مرض رفض الخلايا المزروعة للجسم.
JOP/2017/0065A 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4 JO3242B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
JO3242B1 true JO3242B1 (ar) 2018-03-08

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Country Status (29)

Country Link
US (3) US8765125B2 (ar)
EP (2) EP2528946B1 (ar)
JP (2) JP5883801B2 (ar)
KR (2) KR101832118B1 (ar)
CN (2) CN102947336B (ar)
AR (1) AR080026A1 (ar)
AU (2) AU2011210773B2 (ar)
BR (2) BR112012018820A8 (ar)
CA (2) CA2787615C (ar)
CY (2) CY1118223T1 (ar)
DK (2) DK2528945T3 (ar)
ES (2) ES2609663T3 (ar)
HR (2) HRP20170130T1 (ar)
HU (2) HUE031432T2 (ar)
IL (2) IL220887A (ar)
JO (2) JO3183B1 (ar)
LT (2) LT2528946T (ar)
MX (2) MX343555B (ar)
MY (2) MY156353A (ar)
PL (2) PL2528946T3 (ar)
PT (2) PT2528946T (ar)
RS (2) RS55715B1 (ar)
RU (2) RU2587624C2 (ar)
SG (4) SG10201500416RA (ar)
SI (2) SI2528946T1 (ar)
SM (2) SMT201600412B (ar)
TW (2) TWI600433B (ar)
UY (1) UY33206A (ar)
WO (2) WO2011094467A2 (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
KR20120089659A (ko) 2009-08-29 2012-08-13 아보트 러보러터리즈 치료용 ｄｌｌ4 결합 단백질
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
EP3680253A3 (en) 2010-03-02 2020-09-30 AbbVie Inc. Therapeutic dll4 binding proteins
KR102091293B1 (ko) 2011-09-23 2020-03-20 온코메드 파마슈티칼스, 인크. Vegf/dll4 결합제 및 그의 용도
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
ES2742855T3 (es) 2013-07-09 2020-02-17 Ablbio Nueva proteína de objetivo doble que se une específicamente a DLL4 y CEGF, y uso de la misma
US20160245808A1 (en) * 2013-10-17 2016-08-25 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
ES2717661T3 (es) * 2014-04-08 2019-06-24 Fraunhofer Ges Forschung Terapia de combinación para el tratamiento de las enfermedades autoinmunes
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
CN109071644B (zh) 2015-09-23 2023-09-19 昂考梅德药品有限公司 治疗癌症的方法和组合物
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
BR112021010336A2 (pt) 2018-11-29 2021-08-24 Debora Zucco Sassi Yonezawa Siviglia Método para tratar ou prevenir convulsões associadas a um distúrbio epiléptico
JPWO2022210802A1 (ar) * 2021-03-30 2022-10-06
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
IL165304A0 (en) * 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
BRPI0710413A2 (pt) * 2006-06-06 2011-08-23 Genentech Inc anticorpos anti-dll4, isolados, polinucleotìdeo, vetor, célular hospedeira, método para produção de um anticorpo anti-dll4, método para produção de um imunoconjugado anti-dll4, método para a detecção de dll4, metodo para diagnosticar um distúrbio, composições, método para tratar um tumor, cáncer e/ou disturbio da proliferação celular e método para melhorar a eficácia de um agente anti-angiogênico
BRPI0710411A2 (pt) 2006-06-06 2012-04-10 Genentch Inc Empresa Americana Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
NZ574794A (en) 2006-08-07 2011-06-30 Regeneron Pharma Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
KR20120089659A (ko) * 2009-08-29 2012-08-13 아보트 러보러터리즈 치료용 ｄｌｌ4 결합 단백질
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
CA2787394C (en) 2019-01-08
KR20120123745A (ko) 2012-11-09
IL220887A (en) 2017-07-31
US20110189176A1 (en) 2011-08-04
HRP20170249T1 (hr) 2017-04-07
JP2013518122A (ja) 2013-05-20
WO2011094467A2 (en) 2011-08-04
SI2528945T1 (sl) 2017-01-31
EP2528945B1 (en) 2016-10-26
SMT201700021B (it) 2017-03-08
BR112012018766A2 (pt) 2017-01-10
CA2787615C (en) 2019-01-15
DK2528945T3 (en) 2017-02-06
IL220889A0 (en) 2012-09-24
JP5883801B2 (ja) 2016-03-15
CY1118551T1 (el) 2017-07-12
CN102947336A (zh) 2013-02-27
AU2011210773B2 (en) 2015-11-19
CA2787615A1 (en) 2011-08-04
EP2528946A1 (en) 2012-12-05
JP2013518123A (ja) 2013-05-20
HUE031432T2 (en) 2017-07-28
KR101832118B1 (ko) 2018-02-26
LT2528945T (lt) 2017-01-25
PL2528945T3 (pl) 2017-02-28
TW201136601A (en) 2011-11-01
RU2012136816A (ru) 2014-03-10
RU2587624C2 (ru) 2016-06-20
PT2528945T (pt) 2016-12-14
SMT201600412B (it) 2017-01-10
SG182528A1 (en) 2012-08-30
MX343553B (es) 2016-11-10
RS55595B1 (sr) 2017-06-30
US8889133B2 (en) 2014-11-18
SG10201500416RA (en) 2015-04-29
MY156538A (en) 2016-02-26
PT2528946T (pt) 2016-12-14
TW201615207A (zh) 2016-05-01
CY1118223T1 (el) 2017-06-28
AU2011210773A1 (en) 2012-08-23
AU2011210771B2 (en) 2015-12-10
SI2528946T1 (sl) 2017-01-31
MX343555B (es) 2016-11-10
UY33206A (es) 2011-08-31
MX2012008638A (es) 2012-12-05
ES2609663T3 (es) 2017-04-21
WO2011094465A4 (en) 2011-09-22
US8765125B2 (en) 2014-07-01
RU2012136817A (ru) 2014-03-10
US20110189200A1 (en) 2011-08-04
TWI564019B (zh) 2017-01-01
CN102947336B (zh) 2015-12-02
TWI600433B (zh) 2017-10-01
RS55715B1 (sr) 2017-07-31
DK2528946T3 (en) 2017-02-20
KR101797918B1 (ko) 2017-11-15
WO2011094467A3 (en) 2011-12-22
ES2605430T3 (es) 2017-03-14
SG182527A1 (en) 2012-08-30
AR080026A1 (es) 2012-03-07
KR20130008017A (ko) 2013-01-21
MX2012008740A (es) 2012-08-31
EP2528946B1 (en) 2016-11-16
CA2787394A1 (en) 2011-08-04
HUE032985T2 (en) 2017-11-28
MY156353A (en) 2016-02-15
JO3183B1 (ar) 2018-03-08
WO2011094465A1 (en) 2011-08-04
LT2528946T (lt) 2017-01-25
SG10201500404QA (en) 2015-03-30
IL220889A (en) 2017-07-31
HRP20170130T1 (hr) 2017-03-24
RU2587620C2 (ru) 2016-06-20
JP5997613B2 (ja) 2016-09-28
PL2528946T3 (pl) 2017-04-28
BR112012018820A2 (pt) 2017-01-10
US20140255429A1 (en) 2014-09-11
CN102884081A (zh) 2013-01-16
BR112012018820A8 (pt) 2018-03-13
EP2528945A2 (en) 2012-12-05
AU2011210771A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
UA115540C2 (uk) Антитіло до il-36r
TN2012000555A1 (en) Antibodies to human gdf8
MX2013008833A (es) Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201391735A1 (ru) Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
WO2013067451A3 (en) Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2011004028A3 (en) Tlr3 binding agents
JO3097B1 (ar) الأجسام المضادة c-Met
MX360620B (es) Anticuerpos anti kit y usos de los mismos.
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
NZ609887A (en) Antibody against human prostaglandin e2 receptor ep4
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2010007376A3 (en) Compositions monovalent for cd28 binding and methods of use
EA201290977A1 (ru) Гуманизированные антитела к il-25
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
WO2012138102A3 (ko) Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
NZ624534A (en) Anti-fgfr2 antibodies and uses thereof